UNASSIGNED: From December 2003 to June 2023, 137 patients with advanced HCC receiving systemic chemotherapies (SOR: n=43, LEN: n=16, ATZ+BEV: n=18, HAIC: n=60) were enrolled.
UNASSIGNED: Overall survival (OS) and response rates did not differ significantly across treatments (SOR: 8.3 months, LEN: 10.2 months, ATZ+BEV: 8.5 months, HAIC: 7.3 months). Patients on HAIC and LEN had a lower rate of discontinuing treatment within three months compared to those on ATZ+BEV and SOR. HAIC was associated with fewer changes in ALBI score and better preservation of liver function. Multivariate logistic regression identified serum α-fetoprotein >400 ng/ml [hazard ratio (HR)=1.94; p=0.001], tumor count >5 (HR=1.55; p=0.043), and Child-Pugh score (HR=2.53; p=0.002) as independent predictors of OS.
UNASSIGNED: OS and response rates were similar across systemic chemotherapies. Prognosis for HCC in Child-Pugh class B patients was associated with liver function, necessitating further research for optimal treatment.
■从2003年12月至2023年6月,137例接受全身化疗的晚期HCC患者(SOR:n=43,LEN:n=16,ATZBEV:n=18,HAIC:n=60)入组。
■不同治疗组的总生存期(OS)和反应率没有显著差异(SOR:8.3个月,LEN:10.2个月,ATZ+BEV:8.5个月,HAIC:7.3个月)。与接受ATZBEV和SOR的患者相比,接受HAIC和LEN的患者在三个月内停止治疗的比率较低。HAIC与ALBI评分变化较少、肝功能保存较好相关。多因素logistic回归确定血清甲胎蛋白>400ng/ml[风险比(HR)=1.94;p=0.001],肿瘤计数>5(HR=1.55;p=0.043),Child-Pugh评分(HR=2.53;p=0.002)是OS的独立预测因子。
■全身化疗的OS和反应率相似。Child-PughB级肝癌患者的预后与肝功能相关,需要进一步研究以进行最佳治疗。